Monitor the offering close on February 27, 2026, and watch for any subsequent announcements regarding the specific allocation of the $107.6 million in net proceeds, particularly how much will be directed toward advancing Larimar's clinical programs versus general corporate expenses.
LRMR drugs
LRMR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 27 $5.31entry
- T+1 · 9mo ago −1.51%α −1.56% · $5.23
- T+5 · 9mo ago −1.69%α +0.29% · $5.22
- T+20 · 8mo ago −12.99%α −5.44% · $4.62
- T+60 · 6mo ago −34.65%α −44.04% · $3.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Larimar Therapeutics is conducting a follow-on public offering of 20 million shares at $5.00 per share, with underwriters exercising their full option to purchase an additional 3 million shares, resulting in expected net proceeds of approximately $107.6 million. The company plans to use the proceeds for general corporate purposes, including advancing its clinical programs and expanding operations.
Key Financial Metrics
Key Facts
- Larimar Therapeutics is offering 20 million shares of common stock at $5.00 per share
- Underwriters exercised their full option to purchase an additional 3 million shares
- Expected net proceeds after underwriting discounts and commissions are approximately $107.6 million
- J.P. Morgan Securities LLC and Guggenheim Securities, LLC are acting as joint bookrunning managers
- The offering is expected to close on February 27, 2026, subject to customary closing conditions
Financial Impact
Approximately $107.6 million in net proceeds after underwriting discounts and commissions from the sale of 23 million shares at $5.00 per share
Risk Factors
- Dilution to existing shareholders from the issuance of 23 million new shares
- Potential downward pressure on stock price due to increased share supply
- Uncertainty around how effectively the company will deploy the raised capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-077646 |
| Document: d120172d8k.htm | 0001193125-26-077646 |
| Document: d120172dex51.htm | 0001193125-26-077646 |
| Document: 0001193125-26-077646-index-headers.html | 0001193125-26-077646 |
| Document: 0001193125-26-077646-index.html | 0001193125-26-077646 |
| Document: 0001193125-26-077646.txt | 0001193125-26-077646 |
Track record
13 reports on LRMR
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.13% at T+20 after the Sep 22, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $3.00 Now $3.00 0.00% settles Feb 12
- Nov 16, 2026today Press Release Bullish 7/10 Entry $3.10 Now $3.00 −3.23% settles Feb 12
- Nov 12, 20264d ago Insider Cluster Bullish 4/10 Entry $3.02 Now $3.00 −0.66% settles Feb 11
- Nov 9, 20267d ago 8-K Bullish 7/10 Entry $2.69 Now $3.00 +11.52% settles Feb 8
- Nov 5, 202611d ago Press Release Neutral 2/10 Entry $2.39 Now $3.00 +25.52% settles Feb 4
- Sep 29, 20266w ago Press Release Neutral 3/10 Entry $3.20 Now $3.00 −6.10% settles Dec 24
- Sep 22, 20267w ago Institutional Cluster Bearish 4/10 Entry $3.82 Now $3.00 +21.47% settles Dec 16
- May 14, 202626w ago 8-K Bullish 7/10 No price data
- May 14, 202626w ago Press Release Bullish 7/10 Entry $3.89 to $4.01 Now $3.00 −22.88% ▲ +3.08% −0.50% vs SPY
- Mar 19, 202634w ago Press Release Mixed 7/10 Entry $4.47 to $3.59 Now $3.00 −32.89% ▼ −19.69% −34.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers